Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 2017

View Archived Issues

Promentis Pharmaceuticals completes series C financing and elects new board members

Symproic approved in Japan for the treatment of opioid-induced constipation

Antiva raises series C financing to support development of ABI-1968

LAM Therapeutics closes series C financing

Takeda and MMV establish new joint research program in malaria

CARB-X funds projects to tackle antibiotic resistance

Calypso Biotech and EA Pharma enter CALY-001 license agreement

First patient dosed in phase II study of ARGX-113 in ITP

No statistically significant PT-specific antibody responses seen in phase I trial of Viaskin rPT

SRI International receives FDA clearance to evaluate novel oral formulation of Zn-DTPA

FDA grants orphan drug status to miRagen's MRG-106

NIAID initiates phase II/IIb study of DNA vaccine to protect against Zika virus infection

Munipharma's Mundesine capsules approved in Japan

Incyte gives updates on epacadostat combination studies

Saniona initiates phase IIa study of Tesomet in patients with Prader-Will syndrome

HMBD-001, a novel anti-ERBB3 antibody that inhibits tumor growth in preclinical models

XOMA-129 prevents hypoglycemia in minipigs

European Commission approves Tafinlar with Mekinist for BRAF V600-positive NSCLC

Espero Pharmaceuticals and Armetheon plan to merge and create Espero BioPharma

FDA grants regular approval and expanded indication to Pfizer's Ibrance

Opthea reports results from phase I/IIa trial of OPT-302 in wet AMD

Anti-HER2 scFv-Fc(Ser396Sec)/CN29 is a novel selenomab drug conjugate with activity in vivo

Kite completes rolling BLA submission for axicabtagene ciloleucel

SR-3306 study shows targeting JNK3 may improve Alzheimer's disease

Potential role of adaptive immune response in regulating ZIKV infection and preventing disease

Novel cyclin-dependent kinase inhibitors discovered at Dana-Farber Cancer Institute

Japanese approval for Narurapid and Narusus tablets to treat cancer pain

Janssen decides not to advance phase II study of daratumumab in NHL

Redx Pharma identifies novel antibacterial compounds

Janssen, Katholieke Universiteit Leuven patent dengue virus replication inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...